Phosphagenics reports pain relief
Monday, 08 December, 2008
Phosphagenics has completed a Phase I trial for its drug delivery system TPM to deliver lidocaine topically.
The trial, to assess the bioavailability, safety and tolerability of the application, found the formulation was able to deliver more of the pain relief drug to the skin compared to a leading commercial product, Xylocaine, marketed by AstraZeneca.
The open label, single centre study was conducted at the Centre for Pharmaceutical Research at the University of South Australia in 11 healthy adult volunteers.
TPM is being trialled in a number of small molecule delivery applications, including hormones, morphine and oxycodone. It is also being expanded to large molecule applications, such as peptides.
The company’s lead product is Phospha E, a vitamin E derivative it is exploring as a neutraceutical.
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
